India’s Reliance Freezes Plans For Pharmaceutical Plant, But Ramps Up Entry Into Biopharma With 14 Biosimilars In The Works
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - The tough economic environment seems to have short-circuited the ambitions of Reliance Industries - India's largest private sector group - to emerge as a formidable player in the global pharmaceutical industry. Reliance has frozen all its plans to build a finished formulation facility at Jamnagar - a town near the company's super-size petrochemicals refinery complex
You may also be interested in...
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required.)